Use of vaccinia virus deleted for the E3L gene as a vaccine vector

• US 7,431,929 B2
• Filed: 12/22/2004
• Issued: 10/07/2008
• Est. Priority Date: 07/24/2002
• Status: Expired due to Fees

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Jacobs, Bertram, Talasela, Latha, Vijaysri, Sangeetha, Jancovich, James
• Primary Examiner(s): Mosher; Mary E
• Application Number:
  US11/022,477
• Publication Number:
  US 20060008470A1
• Time in Patent Office: 1,385 Days
• Field of Search: None
• US Class Current: 424/199.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/285 Vaccinia virus or variola virus
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector

Abstract

The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses containing an inactivated E3L region. The invention also relates to methods for stimulating a protective immune response in an immunized host using the vaccines of the invention. The invention is based on the discovery that vaccinia virus mutants having deletions in the E3L region exhibit dramatically reduced pathogenesis while remaining highly immunogenic. In addition, the invention relates to modified recombinant vaccinia viruses engineered to express heterologous polypeptides and the use of such viruses in vaccines designed to stimulate a protective immune response against such polypeptides in a host. The invention further relates to an interferon-sensitive recombinant vaccinia virus with broad host range wherein a salamander eIF2α is inserted into the viral genome in place of at least a portion of the E3L gene.

Claims

1. A recombinant vaccinia virus comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO:

1.

4. A vaccine produced using the recombinant virus of any one of claims 1, 2 or 3.

5. A method of stimulating a mammal to produce antiviral antibodies comprising contacting the mammal with a recombinant vaccinia virus of any one of claims 1, 2 or 3.

6. An expression vector comprising the recombinant vaccinia virus of any one of claims 1, 2 or 3 wherein said vector further comprises exogenous DNA operably linked to regulatory elements that control expression of said exogenous DNA.

2. A recombinant vaccinia virus lacking at least a portion of the vaccinia E3L gene and comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO:

1.

3. The recombinant vaccinia virus of claim 2, wherein the vaccinia E3L gene is deleted and the nucleic acid encoding the amino acid sequence of SEQ ID NO:

1 is inserted in its place.